|Day Low/High||122.32 / 125.47|
|52 Wk Low/High||55.00 / 133.62|
Incyte Corporation (Nasdaq: INCY) announces that more than 15 abstracts highlighting its research and development portfolio in immuno-oncology and targeted therapies will be presented at the upcoming 2017 American Society...
IBM's busted turnaround and difficult transition story shaved more than 50 points off the Dow, says Jim Cramer.
Insiders at Wells Fargo & Company, Incyte and three other companies have been scooping up shares of their own stock lately.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CUDA, ELS, EMN, FCFS, FSIC, HLF, INCR, PAYC, PBHC, PNR, SABR, SFLY, UTSI, VNOM, WB Downgrades: CUI, IGLD, INCY, MTSC, RUBI, TSEM Initiations: AFI Read on to get TheStreet Quant Ratings' detailed report:
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 10:00 a.
Stocks close in positive territory Monday ahead of a big week for U.S. corporate earnings.
Stocks remained in positive territory breaking a three-day losing streak ahead of U.S. corporate earnings this week, despite mounting tension between North Korea and the U.S.
Because there are other things that will take the wind out of your sails.
Stocks rise on Monday ahead of a big week for U.S. corporate earnings, including reports Monday from Netlfix and United Airlines.
Stocks rise on Monday ahead of a big week for U.S. corporate earnings and as the U.S. issues a warning to North Korea.
The FDA action was a win for Pfizer because Xeljanz escapes competition for one year or more.
OncoMed Pharmaceuticals, Incyte and Omeros were among the biotech stock movers in premarket trading on Monday.
The drug was expected to bring in more than $1 billion in sales by 2020.
Stock futures turn higher on Monday ahead of a big week for U.S. corporate earnings and as the U.S. issues a warning to North Korea.
U.S. stock futures are lower Monday following economic data that came in soft and after the U.S. warns North Korea that its patience with the rogue nation is running out.
Doug Kass shares his thoughts on whether Judgment Day is here for the financials and discusses General Electric, Apple and Caterpillar.
Gilead, Pfizer, Abbvie stand to gain from Lilly and Incyte Rheumatoid Arthritis Setback.
Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that the U.
Morgan Stanley raised Incyte's price target to $150.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer is fond of Incyte INCY shares.
Loss of bank leadership and the recent pullback are major factors in what's ailing the markets, says Jim Cramer.
Doug Kass shares his thoughts on Tesla and the second quarter.
'These companies are all assessing the Trump effect,' Cramer said.